Preparation and biodistribution of 59Fe-radiolabelled iron oxide nanoparticles

Pospisilova, Martina; Zapotocky, Vojtech; Nešporová, Kristina; Lázníček, Milan; Lázníčková, Alice; Židek, Ondřej; Cepa, J.; Vágnerová, Hana; Velebný, Vladimı́r

doi:10.1007/s11051-016-3719-0

Cited by 9 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SPIONs have attracted wide attention due to their unique properties originating from intrinsic magnetic properties (due to ferromagnetic iron), high surface area-to-volume ratio, and the ability to chemically modify their core composition and their surfaces. In previous works, SPIONs have been assembled with a series of radionuclides including 18 F [21], 59 Fe [22], 64 Cu [23,24], 89 Zr [25], 99m Tc [26], 111 In [27] and 223 Ra [28]. There are two strategies for the synthesis of radioactive SPIONs: incorporation into the structure or surface functionalization (including the construction of shell layers).…”

Section: Introductionmentioning

confidence: 99%

Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with 225Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast Cancer

et al. 2020

View full text Add to dashboard Cite

It has been proven and confirmed in numerous repeated tests, that the use of a combination of several therapeutic methods gives much better treatment results than in the case of separate therapies. Particularly promising is the combination of ionizing radiation and magnetic hyperthermia in one drug. To achieve this objective, magnetite nanoparticles have been modified in their core with α emitter 225Ac, in an amount affecting only slightly their magnetic properties. By 3-phosphonopropionic acid (CEPA) linker nanoparticles were conjugated covalently with trastuzumab (Herceptin®), a monoclonal antibody that recognizes ovarian and breast cancer cells overexpressing the HER2 receptors. The synthesized bioconjugates were characterized by transmission electron microscopy (TEM), Dynamic Light Scattering (DLS) measurement, thermogravimetric analysis (TGA) and application of 131I-labeled trastuzumab for quantification of the bound biomolecule. The obtained results show that one 225Ac@Fe3O4-CEPA-trastuzumab bioconjugate contains an average of 8–11 molecules of trastuzumab. The labeled nanoparticles almost quantitatively retain 225Ac (>98%) in phosphate-buffered saline (PBS) and physiological salt, and more than 90% of 221Fr and 213Bi over 10 days. In human serum after 10 days, the fraction of 225Ac released from 225Ac@Fe3O4 was still less than 2%, but the retention of 221Fr and 213Bi decreased to 70%. The synthesized 225Ac@Fe3O4-CEPA-trastuzumab bioconjugates have shown a high cytotoxic effect toward SKOV-3 ovarian cancer cells expressing HER2 receptor in-vitro. The in-vivo studies indicate that this bioconjugate exhibits properties suitable for the treatment of cancer cells by intratumoral or post-resection injection. The intravenous injection of the 225Ac@Fe3O4-CEPA-trastuzumab radiobioconjugate is excluded due to its high accumulation in the liver, lungs and spleen. Additionally, the high value of a specific absorption rate (SAR) allows its use in a new very perspective combination of α radionuclide therapy with magnetic hyperthermia.

show abstract

Section: Introductionmentioning

confidence: 99%

Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with 225Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Several methods have been used for radiolabelling MNPs, for example, using desferrioxamine, DOTA, or bisphosphonates for 99m Tc, 64 Cu, or 89 Zr radiolabelling, labelling IONP surfaces with 11 C or 14 C, or 125 I, doping 111 In by high‐temperature decomposition in inorganic core, capping oleate ligands with 59 Fe or 51 Cr and chalet‐free strategies. As shown in Figure 2A, several routes can be used for the radiolabelling reactions using precursor labelling or postsynthetic labelling approaches, which differing yields 51 . For instance, IONPs‐[ 99m Tc]TcO 4 −PEG surface‐coated NPs with more than 99% radiolabelling yields was explored for simultaneous visualization of sM/MRI 53 .…”

Section: Different Nanoparticle Systems Used For Delivery Of Radiophamentioning

confidence: 99%

“…(A) A representative scheme for the preparation of radiolabelled magnetic nanoparticles, as reported in Pospisilova et al 51 and (B) a distribution of magnetic nanoparticles observed by PET and NIRF imaging in an ex vivo model, reprinted with permission from Biomaterials (2010, Elsevier) 52 …”

Section: Different Nanoparticle Systems Used For Delivery Of Radiophamentioning

confidence: 99%

Nanoparticulate formulations of radiopharmaceuticals: Strategy to improve targeting and biodistribution properties

Datta

Ray

2020

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

Application of nanotechnology principles in drug delivery has created opportunities for treatment of several diseases. Nanotechnology offers the advantage of overcoming the adverse biopharmaceutics or pharmacokinetic properties of drug molecules, to be determined by the transport properties of the particles themselves. Through the manipulation of size, shape, charge, and type of nanoparticle delivery system, variety of distribution profiles may be obtained. However, there still exists greater need to derive and standardize definitive structure property relationships for the distribution profiles of the delivery system. When applied to radiopharmaceuticals, the delivery systems assume greater significance. For the safety and efficacy of both diagnostics and therapeutic radiopharmaceuticals, selective localization in target tissue is even more important. At the same time, the synthesis and fabrication reactions of radiolabelled nanoparticles need to be completed in much shorter time. Moreover, the extensive understanding of the several interesting optical and magnetic properties of materials in nanoscale provides for achieving multiple objectives in nuclear medicine. This review discusses the various nanoparticle systems, which are applied for radionuclides and analyses the important bottlenecks that are required to be overcome for their more widespread clinical adaptation.

show abstract

“…The development of superparamagnetic iron oxide nanoparticles (SPIONs) for diagnosis and/or bimodal cancer therapy, using magnetic hyperthermia and radionuclides, has grown considerably over recent years [47][48][49][50]. Mokhodoeva and collaborators described the incorporation of 223Ra (radium-223), the first clinically approved alpha-emitter, into SPIONs.…”

Section: Heating Modalities Used To Induce Hyperthermiamentioning

confidence: 99%

“…On the other hand, SPIONs with 99mTc could be used for diagnostic imaging purposes [49]. Studies by Pospisilova and collaborators reported the incorporation of radionuclide 59Fe (iron-59) into SPIONs [50]. Separate studies showed the incorporation of 59Fe and 111In (índium-111) into SPIONs [47].…”

Section: Heating Modalities Used To Induce Hyperthermiamentioning

confidence: 99%

Thermosensitive Nanosystems Associated with Hyperthermia for Cancer Treatment

et al. 2019

View full text Add to dashboard Cite

Conventional chemotherapy regimens have limitations due to serious adverse effects. Targeted drug delivery systems to reduce systemic toxicity are a powerful drug development platform. Encapsulation of antitumor drug(s) in thermosensitive nanocarriers is an emerging approach with a promise to improve uptake and increase therapeutic efficacy, as they can be activated by hyperthermia selectively at the tumor site. In this review, we focus on thermosensitive nanosystems associated with hyperthermia for the treatment of cancer, in preclinical and clinical use.

show abstract

Preparation and biodistribution of 59Fe-radiolabelled iron oxide nanoparticles

Cited by 9 publications

References 38 publications

Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with 225Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast Cancer

Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with 225Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast Cancer

Nanoparticulate formulations of radiopharmaceuticals: Strategy to improve targeting and biodistribution properties

Thermosensitive Nanosystems Associated with Hyperthermia for Cancer Treatment

Contact Info

Product

Resources

About